Plozasiran, previously called ARO-APOC3, is a first-in-class investigational RNA interference (RNAi) therapeutic that is specifically designed to actively suppress hepatic production of apolipoprotein C-III (APOC3), a critical structural and functional component of triglyceride-rich lipoproteins (TRLs) and a central regulator of systemic triglyceride metabolism, thereby addressing dyslipidemia at the level of gene expression through targeted post-transcriptional silencing mechanisms.
Molekulargewicht:
15618.77
CAS Nummer:
[2379776-40-4]
Target-Kategorie:
Apolipoprotein
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
